Coherus Biosciences Receives FDA Supplemental Approval For Yusimry 40MG On BLA 761216
Portfolio Pulse from Charles Gross
Coherus Biosciences has received FDA supplemental approval for Yusimry 40MG on BLA 761216. The approval allows for the inclusion of treatment of non-infectious intermediate, posterior and panuveitis in adult patients.
September 14, 2023 | 5:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Coherus Biosciences has received FDA approval for expanded use of Yusimry 40MG. This could potentially increase the company's market share and revenues.
FDA approval for expanded use of a drug typically leads to increased sales and revenues for the company. This is because the approval allows the company to market the drug for additional uses, potentially reaching a larger patient population. Therefore, this news is likely to have a positive impact on Coherus Biosciences' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100